Keywords: Antisense Oligonucleotide, Aortic Valve Stenosis, Cardiovascular Disease, Lipoprotein (a), Lipoprotein(a) Screening, Oxidized Phospholipids, PCSK9 Inhibitors, RNA Interference
Introduction: The Billion-Person Blind Spot
Cardiovascular disease (CVD) remains the leading cause of death globally, responsible for an estimated 17.9 million deaths per year. Despite remarkable advances in lipid management like statins, PCSK9 inhibitors, and lifestyle modification, a substantial proportion of high-risk individuals continue to suffer heart attacks and strokes even when LDL cholesterol is well controlled. A growing body of evidence points to Lp(a) as one of the most important, yet systematically underappreciated, explanations for this residual risk [1,2].
Lp(a) is elevated, defined by most international bodies as above 50 mg/dL or 125 nmol/L, in roughly 20% of the global population, placing more than one billion people in a category of genetically mediated cardiovascular risk they may never know they carry. Standard lipid panels do not include Lp(a). Most primary care practitioners do not routinely test for it. And until very recently, there was little clinical reason to measure Lp(a) because no approved drug could significantly lower it [3].
That equation is changing rapidly. The convergence of RNA interference technology, antisense oligonucleotide therapy, and small-molecule innovation has produced multiple agents currently in Phase 2 and Phase 3 trials capable of reducing Lp(a) by 70 to 98%. For clinicians, researchers, and individuals invested in their own longevity, understanding Lp(a) is no longer optional, it is essential [1,2,5].
What Exactly is Lp(a)? Structure, Genetics, and Why it Matters
Molecular Architecture
Lp(a) is structurally similar to LDL, it has a core of cholesterol esters and triglycerides surrounded by a phospholipid shell, but with one decisive difference: a large, hydrophilic glycoprotein called apolipoprotein(a), or apo(a), covalently bonded to apolipoprotein B-100 (apoB-100) via a single disulfide bridge. This unique molecular partnership is what gives Lp(a) its distinctive and dangerous properties [4].
Apo(a) was first described in 1987 by McLean and colleagues, who discovered its remarkable structural homology to plasminogen, the precursor to plasmin, the body’s primary clot-dissolving enzyme. Apo(a) contains multiple repeating units called kringle domains, particularly kringle IV (KIV) and kringle V, which are nearly identical in sequence to those found in plasminogen. This similarity is not coincidental: it has profound functional consequences. Because apo(a) competes with plasminogen for binding sites on fibrin and cell-surface receptors, it can directly impair fibrinolysis, the process by which blood clots are dissolved. In practical terms, elevated Lp(a) promotes clot persistence and formation, not just plaque buildup [4].
The LPA Gene and Kringle Copy Number Variation
The LPA gene, located on chromosome 6q26-27, encodes apolipoprotein(a). What makes this gene biologically unusual is the number of kringle IV type 2 (KIV-2) repeats it contains, which varies enormously between individuals, from as few as 2 to as many as 40 copies. This is copy number variation, and it has an inverse relationship with Lp(a) plasma concentration: individuals with fewer KIV-2 repeats produce smaller apo(a) isoforms, which are more efficiently secreted by the liver and correlate with higher circulating Lp(a) levels [16].
Critically, approximately 70 to 90% of the variation in plasma Lp(a) concentration is genetically determined. This means lifestyle interventions such as dietary changes, exercise, weight loss, have minimal impact on Lp(a) levels in the vast majority of people. This stands in stark contrast to LDL cholesterol, which is highly modifiable by diet and medication. Two individuals eating identical diets and exercising equally can have vastly different Lp(a) levels based entirely on their inherited LPA genotype. This genetic determinism is both sobering and clarifying: if you have high Lp(a), it is not your fault, and it requires targeted pharmacological attention [9].
Additional single nucleotide polymorphisms (SNPs) in the LPA gene region, particularly rs10455872 and rs3798220 are strongly associated with elevated Lp(a) and have been identified in genome-wide association studies (GWAS) as robust, independent predictors of myocardial infarction, stroke, and peripheral arterial disease [3,16].
Ethnic and Population Variation
Lp(a) levels vary significantly by ethnicity, a fact with important implications for population-based screening. Individuals of African descent have substantially higher median Lp(a) concentrations compared to those of European or Asian ancestry, in some studies, two to three times higher. Despite this, the clinical guidelines and risk thresholds have largely been developed in predominantly European cohorts, raising concerns about equity in both screening and therapeutic development. South Asian populations also demonstrate higher Lp(a) concentrations and may be at particular risk given their already-elevated baseline cardiovascular risk profile. These disparities underscore the need for population-specific normative data and inclusive clinical trial design [5].
How Lp(a) Damages the Heart and Vasculature
Accelerated Atherosclerosis
Like LDL, Lp(a) deposits cholesterol within the arterial wall, driving atherosclerotic plaque formation. However, Lp(a) is not simply a renamed version of LDL, it carries additional atherogenic cargo that amplifies its damaging effects. Chief among these are oxidized phospholipids (OxPL), which become concentrated on the surface of Lp(a) particles at levels approximately 10 times higher than on LDL itself [6].
OxPL are potent pro-inflammatory molecules. They activate endothelial cells, promote the expression of vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1), stimulate macrophage foam cell formation, and upregulate genes involved in plaque instability and rupture. Boffa and Koschinsky proposed that OxPL carried by Lp(a) represent the unifying mechanism by which Lp(a) drives not only coronary artery disease but also peripheral vascular disease and aortic stenosis, a framework that has gained substantial acceptance in the field [6,7].
Prothrombic Activity
The structural homology between apo(a) and plasminogen gives Lp(a) a unique prothrombotic character absent from other lipoproteins. By competing with plasminogen for binding to fibrin and tissue plasminogen activator (tPA), Lp(a) inhibits clot dissolution and tips the coagulation balance toward thrombosis. Apo(a) also interacts directly with platelet receptors and can promote platelet aggregation. This dual capacity, to both deposit cholesterol in vessel walls and impair clot clearance, means that Lp(a) increases the risk of both plaque rupture (the initiating event of most heart attacks) and the subsequent failure to resolve the resulting thrombus [7].
Aortic Valve Calcification and Stenosis
One of the most compelling discoveries in recent Lp(a) research is its causal link to calcific aortic valve stenosis (CAVS), a condition in which calcium deposits progressively narrow the aortic valve opening. Thanassoulis and colleagues, in a landmark 2013 GWAS published in The New England Journal of Medicine, identified the rs10455872 variant in the LPA gene as the strongest genetic predictor of valvular calcification and aortic stenosis. OxPL carried by Lp(a) drive osteoblast-like differentiation of valve interstitial cells, promoting calcium deposition on the valve leaflets. Bergmark and colleagues subsequently demonstrated that PCSK9 inhibition, which modestly reduces Lp(a) by approximately 20%, was associated with a lower rate of aortic valve events in the FOURIER trial. Aortic stenosis is increasingly recognised as a lipid-driven, inflammatory condition, not merely mechanical wear and tear and Lp(a) sits at its centre [8,20].
Risk Stratification and Screening: Who Should Be Tested and What Do the Numbers Mean
Measuring Lp(a): Units, assays, and Standardization
Lp(a) can be measured in milligrams per decilitre (mg/dL), reflecting total particle mass, or nanomoles per litre (nmol/L), reflecting particle number. Because apo(a) isoform size varies substantially between individuals, mass-based measurements can be misleading: a person with large apo(a) isoforms may have the same Lp(a) mass as someone with small isoforms but fewer, less atherogenic particles. For this reason, the European Atherosclerosis Society (EAS) consensus statement recommends nmol/L as the preferred unit, with a threshold of 125 nmol/L (approximately 50 mg/dL) as the boundary for elevated cardiovascular risk [1].
There is no need to fast before an Lp(a) blood test, concentrations are not significantly affected by recent food intake, unlike triglycerides. This makes Lp(a) testing convenient and accessible. However, significant interlaboratory variability persists, and standardisation of assays remains an ongoing challenge. The WHO International Reference Preparation (NIBSC 2B/02) has been developed to improve assay comparability, but not all clinical laboratories yet use calibrated assays [10].
What the Threshold Numbers Actually Mean
Large prospective studies, including the Copenhagen City Heart Study involving tens of thousands of participants followed for decades, have established a clear dose-dependent relationship between Lp(a) concentration and cardiovascular event risk. Individuals with Lp(a) above 50 mg/dL have approximately a 1.5-fold increase in myocardial infarction risk compared to those in the normal range. Those above 90 mg/dL face a 2-fold increase. In the highest decile, above approximately 180 mg/dL, the risk approaches that seen in heterozygous familial hypercholesterolaemia, a well-recognized severe genetic lipid disorder [17,23].
Crucially, the risk conferred by Lp(a) is largely independent of LDL cholesterol levels. A person with optimally controlled LDL but markedly elevated Lp(a) remains at substantially elevated cardiovascular risk, a reality that current standard-of-care risk calculators systematically underestimate. The 2018 AHA/ACC Blood Cholesterol Guidelines include Lp(a) as a risk-enhancing factor that may inform the decision to initiate or intensify statin therapy, but stop short of mandating universal screening [5,19].
Who Should be Screened?
The EAS consensus recommends that Lp(a) be measured at least once in every adult’s lifetime, ideally during routine lipid screening in young adulthood. Cascade testing, offering Lp(a) measurement to first-degree relatives of anyone found to have elevated Lp(a) is particularly important given the high heritability of the trait. Priority groups for testing include individuals with: premature cardiovascular disease (men under 55, women under 65); a family history of early heart disease or stroke; recurrent cardiovascular events despite statin therapy; borderline or intermediate 10-year cardiovascular risk where an additional risk stratifier could guide treatment decisions; and any personal or family history of familial hypercholesterolaemia, since the two conditions frequently co-occur and their combined risk is multiplicative rather than additive [1,21,24].
From a longevity medicine perspective, Lp(a) testing ideally belongs in every comprehensive metabolic and cardiovascular health panel, not as a diagnostic curiosity, but as an actionable piece of lifetime risk intelligence. Knowing one’s Lp(a) level by age 30 or 40 allows for decades of proactive risk reduction: earlier initiation of statin or PCSK9 inhibitor therapy to drive LDL as low as possible, aggressive management of all modifiable risk factors, and, in the near future, access to specific Lp(a)-lowering agents.
What Existing Therapies Can and Cannot Do About Lp(a)
The longstanding frustration in managing elevated Lp(a) has been therapeutic: most conventional interventions simply do not work. Statins, the backbone of CVD prevention have no meaningful effect on Lp(a) and may in fact raise it modestly in some individuals. Diet and exercise changes produce negligible reductions. Niacin (nicotinic acid) can lower Lp(a) by 20 to 30%, but its use has declined sharply after clinical trials failed to demonstrate a reduction in cardiovascular events, and its side-effect profile limits its acceptability [5,9].
PCSK9 inhibitors, evolocumab and alirocumab are potent LDL-lowering drugs that also reduce Lp(a) by approximately 20 to 30%. This is a clinically meaningful reduction for individuals at the high end of the risk spectrum, and these drugs are indicated in patients with very high cardiovascular risk, but the Lp(a)-lowering effect is insufficient to normalise concentrations in those with severely elevated levels. Lipoprotein apheresis, a dialysis-like procedure that physically removes Lp(a) from the bloodstream is effective and approved in some jurisdictions for patients with extremely high Lp(a) and progressive cardiovascular disease, but is expensive, invasive, and requires repeated sessions every one to two weeks [2,11].
The Therapeutic Revolution: RNA-Targeting and Small-Molecule Approaches
Pelacarsen (Antisense Oligonucleotide)
Pelacarsen (TQJ230, Novartis/Ionis) is an antisense oligonucleotide (ASO) that targets the messenger RNA encoding apo(a) in liver cells, preventing its translation into protein. In the Phase 2 APOLLO trial, pelacarsen reduced Lp(a) by up to 80% compared to placebo, with an impressive safety and tolerability profile. The mechanism is elegant: by degrading the LPA mRNA before translation, pelacarsen eliminates the problem at its source. The Phase 3 Lp(a)HORIZON trial enrolled over 8,000 patients with established CVD and Lp(a) above 70 mg/dL, and its results are among the most anticipated in cardiovascular medicine. If outcomes data confirm that Lp(a) lowering by this magnitude translates into reduced major adverse cardiovascular events (MACE), it will establish definitive proof of causality and likely trigger a complete overhaul of cardiovascular risk guidelines [13].
Olpasiran (Small Interfering RNA)
Olpasiran (AMG890, Amgen) uses RNA interference (RNAi) technology to silence the LPA gene. Small interfering RNA (siRNA) molecules are delivered to hepatocytes via GalNAc (N-acetylgalactosamine) conjugation, exploiting a receptor on liver cells to achieve highly selective uptake. Once inside the cell, the siRNA is loaded into the RNA-induced silencing complex (RISC), which cleaves LPA mRNA and prevents apo(a) synthesis. In the Phase 2 OCEAN(a)-DOSE trial, olpasiran reduced Lp(a) by 71 to 97% compared to placebo, with durable effects lasting up to 12 weeks from a single dose, an extraordinary result suggesting that twice-yearly dosing may be sufficient for sustained Lp(a) control. O’Donoghue and colleagues reported these data in The New England Journal of Medicine in 2022, marking a pivotal moment for the field. The Phase 3 OCEAN(a)-Outcomes trial is now enrolling [12].
Muvalaplin (Oral Small Molecule)
While pelacarsen and olpasiran are injectable agents, muvalaplin (LY3473329, Eli Lilly) represents a potentially more scalable approach: an oral small-molecule inhibitor. Muvalaplin works by disrupting the non-covalent interaction between apo(a) and apoB-100, preventing the assembly of the intact Lp(a) particle before secretion into the bloodstream. In the Phase 2 KRAKEN trial reported in JAMA in 2023, Lincoff and colleagues demonstrated that muvalaplin reduced Lp(a) by up to 85% in a dose-dependent fashion, with good tolerability. An oral once-daily pill capable of 85% Lp(a) reduction would represent a transformative advance in accessibility, particularly for populations in lower-resource settings where injectable biologics may not be feasible [14].
Additional Agents in the Pipeline
Zerlasiran (SLN360, Silence Therapeutics) is another GalNAc-siRNA in Phase 2 development that has shown greater than 90% Lp(a) reduction in early trials. Lepodisiran (LY3819469, Eli Lilly), an siRNA targeting LPA mRNA, demonstrated 94% Lp(a) reduction at the highest dose in the Phase 2 LIPID-1 trial. The competitive pipeline in Lp(a) therapeutics signals both scientific confidence in the target and the enormous potential public health impact, estimated at over one billion at-risk individuals worldwide. The next three to five years will likely determine which of these agents delivers the best benefit-to-risk profile and in which patient populations [2].
Lp(a) Through the Longevity Lens: Metabolic Disease, Ageing, and Prevention
Lp(a) as a Longevity Risk Factor
From a longevity medicine perspective, Lp(a) is particularly significant for several reasons. First, it begins exerting its atherogenic effects early, potentially from childhood and accumulates risk silently and inexorably over decades. Unlike LDL, which responds to lifestyle change and allows for course correction at any age, elevated Lp(a) represents a fixed, genetically determined background hazard against which all other risk management must be measured [15,16].
A 2023 study by Berman and colleagues in JAMA Cardiology examined the association between Lp(a) levels and longevity in patients presenting for preventive cardiology evaluations. The authors found that individuals with very low Lp(a) concentrations (below 15 nmol/L) had significantly greater odds of being long-lived (survival past age 90), while those with elevated Lp(a) had shortened cardiovascular health spans. This finding adds Lp(a) to the growing portfolio of biomarkers being evaluated in the context of health span, not just lifespan but also extension [15].
The Metabolic Disease Intersection
Lp(a) and metabolic disease intersect in important and underappreciated ways. Type 2 diabetes is associated with paradoxically lower Lp(a) levels, possibly due to increased hepatic insulin signalling that suppresses LPA gene expression. This means that in diabetic individuals, Lp(a) may fall as their metabolic condition worsens, potentially obscuring the true lipid risk picture. Conversely, individuals with insulin resistance who have not yet developed frank diabetes may carry high Lp(a) alongside elevated triglycerides, low HDL, and small dense LDL, a lipid phenotype particularly associated with inflammatory coronary artery disease [9].
The relationship between Lp(a) and vascular inflammation is also clinically important. OxPL-bearing Lp(a) particles are potent activators of the NLRP3 inflammasome and interleukin-1 beta (IL-1beta) pathway, the same inflammatory axis targeted by canakinumab in the CANTOS trial, which demonstrated that anti-inflammatory therapy reduces cardiovascular events independently of lipid lowering. This positions Lp(a) not just as a lipid problem but as a driver of chronic vascular inflammation, precisely the kind of sustained, low-grade biological stress that accelerates ageing across organ systems and shortens health span [6,7].
What Can Be Done Today While Awaiting Approved Lp(a)-Specific Therapies
In the absence of approved Lp(a)-lowering agents, individuals with elevated Lp(a) should focus on maximizing control of every other modifiable cardiovascular risk factor. The principle is straightforward: if you cannot reduce Lp(a) itself, reduce the harm it causes by minimizing the atherogenic environment in which it operates. This means achieving and maintaining LDL cholesterol as low as possible, ideally below 70 mg/dL in high-risk individuals, or below 55 mg/dL in very high-risk individuals, alongside optimal blood pressure control, non-smoking status, glycaemic control, and maintenance of lean body composition [19,22].
For individuals at high cardiovascular risk with documented high Lp(a), PCSK9 inhibitors offer the best currently available dual benefit, aggressively lowering LDL while modestly reducing Lp(a). Low-dose aspirin therapy may be considered in some high-risk individuals given Lp(a)’s prothrombotic properties, though its benefit-to-bleeding risk ratio requires careful, individualized assessment. From a dietary perspective, while food choices do not substantially alter Lp(a), an anti-inflammatory dietary pattern, high in omega-3 fatty acids, polyphenols, and dietary fibre, attenuates the downstream inflammatory consequences of elevated Lp(a) and supports overall cardiovascular health [11].
Conclusion: A New Paradigm for Cardiovascular Risk
Lipoprotein(a) is one of the most compelling stories in contemporary cardiovascular medicine: a genetically determined, atherogenic lipoprotein particle preset at pathological levels in one in five people, casually implicated in myocardial infarction, stroke, and aortic stenosis, yet largely invisible to standard clinical practice for more than half a century. The convergence of Mendelian randomization genetics, which has provided near definitive proof of causality with a revolutionary wave of RNA-targeting therapeutics means we are approaching an inflection point: the moment when knowing your Lp(a) level transitions from academic curiosity to an actionable, personalized, and potentially life-saving of information.
For those working at the intersection of preventive medicine, longevity science, and AI-enabled health technology, Lp(a) represents exactly the kind of high-signal, under detected biomarker that should be integrated into comprehensive health risk models. The availability of inexpensive, non-fasting Lp(a) testing, combined with the imminent arrival of potent and convenient Lp(a)-lowering agents, makes now the ideal time to embed Lp(a) screening into population health platforms, digital health applications, and preventive cardiology workflows.
The pending outcomes data from the Lp(a)HORIZON and OCEAN(a)-Outcomes trials will be watershed moments for the field. If these trials confirm that 70 to 97% reductions in Lp(a) translate into proportional reductions in cardiovascular events, as the genetics-derived data strongly predict, then the management of elevated Lp(a) will move rapidly from a niche specialty interest to a global public health imperative [1,12,13].
Until then, the most powerful thing any clinician, health professional, or informed individual can do is simple: measure Lp(a) at least once, understand what the result means, and build a risk management strategy accordingly. The cardiovascular risk hiding in plain sight, encoded in DNA, present from birth, and largely undetected is finally, after decades of scientific labor, within reach of effective intervention.
Reference
1. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946.
2. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692-711.
3. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331-2339.
4. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330(6144):132-137.
5. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-2853.
6. Boffa MB, Koschinsky ML. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat Rev Cardiol. 2019;16(5):305-318.
7. Scipione CA, Cybulsky MI, Bhatt DL, Koschinsky ML. New insights into mechanisms underlying lipoprotein(a)-mediated cardiovascular disease. Curr Opin Lipidol. 2021;32(3):167-173.
8. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368(6):503-512.
9. Enkhmaa B, Berglund L. Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis. 2022;349:53-62.
10. Langsted A, Kamstrup PR, Nordestgaard BG. Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk. Atherosclerosis. 2014;234(1):95-101.
11. Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a) responses to evolocumab administration in individuals with and without hyperlipoproteinemia(a). Arterioscler Thromb Vasc Biol. 2019;39(6):1035-1046.
12. O’Donoghue ML, Rosenson RS, Guo J, et al. Small-interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387(20):1855-1864.
13. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244-255.
14. Lincoff AM, Schwartz GG, Nicholls SJ, et al. Muvalaplin for lowering of lipoprotein(a): a randomized clinical trial. JAMA. 2023;330(22):2174-2183.
15. Berman AN, Biery NE, Stealer N, et al. Association of lipoprotein(a) levels with longevity in patients presenting for preventive cardiology evaluations. JAMA Cardiol. 2023;8(7):713-720.
16. Kronenberg F. Human genetics and the causal role of lipoprotein(a) for various diseases. Cardiovasc Drugs Ther. 2016;30(1):87-100.
17. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117(2):176-184.
18. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520-1530.
19. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC guideline on the management of blood cholesterol. Circulation. 2019;139(25):e1082-e1143.
20. Bergmark BA, O’Donoghue ML, Murphy SA, et al. An exploratory analysis of proprotein convertase subtilisin/kexin type 9 inhibition and aortic stenosis in the FOURIER trial. JAMA Cardiol. 2020;5(6):709-713.
21. Mehta A, Virani SS, Alam M, et al. Lipoprotein(a) and family history predict cardiovascular disease risk. J Am Coll Cardiol. 2020;76(7):781-793.
22. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2018;319(15):1566-1579.
23. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412-423.
24. Hopewell JC, Seedorf U, Farrall M, et al. Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med. 2014;276(3):260-268.
25. Anderson TJ, Gregoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32(11):1263-1282.